0001487371-21-000007.txt : 20210121
0001487371-21-000007.hdr.sgml : 20210121
20210121200953
ACCESSION NUMBER: 0001487371-21-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210119
FILED AS OF DATE: 20210121
DATE AS OF CHANGE: 20210121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mendel Scott
CENTRAL INDEX KEY: 0001515051
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34753
FILM NUMBER: 21543417
MAIL ADDRESS:
STREET 1: 5964 LA PLACE COURT
STREET 2: ADDRESS 2
CITY: CARLSBAD
STATE: CA
ZIP: 92008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GenMark Diagnostics, Inc.
CENTRAL INDEX KEY: 0001487371
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 272053069
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5964 LA PLACE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: (760) 448-4300
MAIL ADDRESS:
STREET 1: 5964 LA PLACE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92008
4
1
wf-form4_161127777816658.xml
FORM 4
X0306
4
2021-01-19
0
0001487371
GenMark Diagnostics, Inc.
GNMK
0001515051
Mendel Scott
5964 LA PLACE COURT
CARLSBAD
CA
92008
1
1
0
0
President & CEO
Common Stock
396830
D
Common Stock
2021-01-19
4
S
0
50000
14.54
D
115491
I
Mendel Trust dated October 14, 2011
Common Stock
2021-01-21
4
M
0
50074
0
A
446904
D
Common Stock
2021-01-21
4
M
0
46098
0
A
493002
D
Common Stock
2021-01-21
4
M
0
50000
0
A
543002
D
Market Stock Units
0.0
2021-01-21
4
M
0
50074
0
D
Common Stock
50074.0
0
D
Market Stock Units
0.0
2021-01-21
4
M
0
46098
0
D
Common Stock
46098.0
14167
D
Market Stock Units
0.0
2021-01-21
4
M
0
50000
0
D
Common Stock
50000.0
50000
D
This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by reporting person in July 2020.
The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $14.09 to $14.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Mr. Mendel is the trustee of the Mendel Trust and has voting and dispositive power with respect to these shares. Mr. Mendel disclaims beneficial ownership except to the extent of his pecuniary interest therein.
The MSUs vested in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index.
The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index.
Represents the target number of shares which remain subject to the award.
The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index.
/s/ Eric Stier, Attorney-in-fact
2021-01-21